Skip to main content
CERS
NASDAQ Industrial Applications And Services

Stockholders Approve 10 Million Share Increase for Equity Incentive Plan and Re-elect Directors

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$2.66
Mkt Cap
$532.981M
52W Low
$1.15
52W High
$3.15
52W Position info
131% above low
Off High info
16% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

CERS has more than doubled off its 52-week low of $1.15.

Summary

Cerus stockholders approved a 10 million share increase for the equity incentive plan, representing approximately 5% potential dilution, and re-elected directors, including the Chair/CEO, despite recent shareholder opposition.


Key Events · Corporate Governance and Compliance · CERS

  • Equity Incentive Plan Expanded

    Stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing the shares available for issuance by 10,000,000. This authorization, previously proposed on April 22, 2026, represents approximately 5% potential dilution if all shares are issued for compensation.

  • Director Re-elections Confirmed

    William M. Greenman and Ann Lucena were re-elected to the Board of Directors to serve until the 2029 Annual Meeting. This follows a recent public campaign by a shareholder to withhold votes from the Chair/CEO, William M. Greenman.

  • Executive Compensation Approved

    Stockholders approved, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement.

  • Auditor Ratified

    Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.


Analysis · CERS · Industrial Applications And Services

Stockholders approved a 10 million share increase for the 2024 Equity Incentive Plan, which could lead to approximately 5% dilution for existing shareholders if all shares are issued for compensation. This approval finalizes a proposal previously outlined in the April 22, 2026 proxy statement. Additionally, the re-election of directors, including the Chair/CEO, occurred despite a recent public campaign by a shareholder to withhold votes, indicating management's continued board support.

At the time of this filing, CERS was trading at $2.66 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $533M. The 52-week trading range was $1.15 to $3.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CERS - Latest Insights

CERS
Jun 08, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.60
Real-time Price: $2.90 info
Change: +$0.300 (+12%) info
Market Cap: $581.07M info
CERS
Jun 08, 2026, 8:42 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.71
Real-time Price: $2.90 info
Change: +$0.190 (+7%) info
Market Cap: $581.07M info
CERS
May 27, 2026, 12:52 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $2.82
Real-time Price: $2.90 info
Change: +$0.080 (+3%) info
Market Cap: $581.07M info
CERS
Apr 30, 2026, 5:05 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.16
Real-time Price: $2.90 info
Change: +$0.740 (+34%) info
Market Cap: $581.07M info
CERS
Apr 30, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.25
Real-time Price: $2.90 info
Change: +$0.650 (+29%) info
Market Cap: $581.07M info